Viewpoint: Embracing biosimilars will drive down prices, increase access to drugs


The biosimilar category holds incredible promise, and the market for these products is on an upward trajectory. But it’s been a long journey and biosimilars have faced hurdles at every progression point.

Five years ago, there were only a handful of manufacturers willing to take the risk and get in the game. Look at biosimilars now in the pipeline and studies in progress and you can see legacy brand manufacturers like Pfizer and Amgen, as well as generic manufacturers like Sandoz and Amneal, building biosimilar programs.

The fundamentals are now in place for a market economy to work and create value. We have seen the presence of biosimilars help keep a lid on innovator list price increases.

Related article:  Electrical brain zaps show promise at improving memory in older adults

If regulators, payers, and manufacturers pave the way for increased competition, the U.S. could decrease direct spending on biologics by $54 billion through 2026.

Biosimilar competition could increase access to both biosimilars and biologics for 1.2 million patients by 2025. It’s time that payers recognize the benefits of biosimilars and evaluate fair reimbursement and coverage for these products.

Payers should help create an even playing field for these products. More of them on the market provide physicians with more options to make the best clinical decisions for their patients.

Read the original post

Outbreak Daily Digest
Biotech Facts & Fallacies
Talking Biotech
Genetics Unzipped
ac antarctica feat x

Video: Antarctica research shows how isolation changes the brain

As humans grapple with pandemic-induced isolation, science is starting to offer insight into what may be happening in our brains when ...
mag insects image superjumbo v

Disaster interrupted: Which farming system better preserves insect populations: Organic or conventional?

A three-year run of fragmentary Armageddon-like studies had primed the journalism pumps and settled the media framing about the future ...
dead bee desolate city

Are we facing an ‘Insect Apocalypse’ caused by ‘intensive, industrial’ farming and agricultural chemicals? The media say yes; Science says ‘no’

The media call it the “Insect Apocalypse”. In the past three years, the phrase has become an accepted truth of ...
globalmethanebudget globalcarbonproject cropped x

Infographic: Cows cause climate change? Agriculture scientist says ‘belching bovines’ get too much blame

A recent interview by Caroline Stocks, a UK journalist who writes about food, agriculture and the environment, of air quality ...
organic hillside sweet corn x

Organic v conventional using GMOs: Which is the more sustainable farming?

Many consumers spend more for organic food to avoid genetically modified products in part because they believe that “industrial agriculture” ...
benjamin franklin x

Are most GMO safety studies funded by industry?

The assertion that biotech companies do the research and the government just signs off on it is false ...
gmo corn field x

Do GMO Bt (insect-resistant) crops pose a threat to human health or the environment?

Bt is a bacterium found organically in the soil. It is extremely effective in repelling or killing target insects but ...

Environmental Working Group: EWG challenges safety of GMOs, food pesticide residues

Known by some as the "Environmental Worrying Group," EWG lobbies for tighter GMO legislation and famously puts out annual "dirty dozen" list of fruits and ...
m hansen

Michael Hansen: Architect of Consumers Union ongoing anti-GMO campaign

Michael K. Hansen (born 1956) is thought by critics to be the prime mover behind the ongoing campaign against agricultural biotechnology at Consumer Reports. He is an ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend